Intrust Bank NA Increases Position in Johnson & Johnson (JNJ)

Share on StockTwits

Intrust Bank NA lifted its position in Johnson & Johnson (NYSE:JNJ) by 3.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,319 shares of the company’s stock after purchasing an additional 972 shares during the period. Johnson & Johnson accounts for about 1.1% of Intrust Bank NA’s investment portfolio, making the stock its 13th biggest position. Intrust Bank NA’s holdings in Johnson & Johnson were worth $3,757,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. NuWave Investment Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $680,000. IBM Retirement Fund lifted its holdings in Johnson & Johnson by 4.8% during the fourth quarter. IBM Retirement Fund now owns 70,094 shares of the company’s stock worth $10,697,000 after buying an additional 3,221 shares during the period. Keeler Thomas Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth $2,692,000. OxFORD Asset Management LLP lifted its holdings in Johnson & Johnson by 407.9% during the third quarter. OxFORD Asset Management LLP now owns 27,431 shares of the company’s stock worth $3,561,000 after buying an additional 22,030 shares during the period. Finally, Hefty Wealth Partners lifted its holdings in Johnson & Johnson by 959.3% during the fourth quarter. Hefty Wealth Partners now owns 6,970 shares of the company’s stock worth $974,000 after buying an additional 6,312 shares during the period. Hedge funds and other institutional investors own 65.97% of the company’s stock.

NYSE JNJ opened at $125.00 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.58. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32. The firm has a market capitalization of $329.22 billion, a P/E ratio of 17.12, a PEG ratio of 1.88 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The firm had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. During the same period in the prior year, the firm earned $1.83 EPS. The firm’s revenue was up 12.6% on a year-over-year basis. analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th were given a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.88%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend was Friday, May 25th. Johnson & Johnson’s dividend payout ratio is presently 49.32%.

A number of research firms have weighed in on JNJ. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b” rating in a report on Friday, May 18th. ValuEngine downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. Credit Suisse Group set a $151.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, June 12th. Deutsche Bank reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 18th. Finally, Sanford C. Bernstein began coverage on Johnson & Johnson in a research report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price target on the stock. Six investment analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $141.60.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply